T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

B-Cell Non-Hodgkin Lymphomas including diffuse large B-cell lymphoma, follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), autoimmune hemolytic anemia, hidradenitis ...

Chimeric antigen receptor (CAR) T-cell therapies have proved effective in several haematological cancers including B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, multiple myeloma ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that ...

At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Roche presents new and updated data for fixed-duration Columvi and Lunsumio at ASH 2024 meeting: Basel Wednesday, December 11, 2024, 11:00 Hrs [IST] Roche announced that new and u ...

Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...